TILT Biotherapeutics Ltd.
Haartmaninkatu 3, 4th Floor
C-wing
Helsinki
00290
Website: http://tiltbio.com/
Email: akseli@tiltbio.com
About TILT Biotherapeutics Ltd.
TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of solid tumors as currently achieved for CD19+ hematological tumors.YEAR FOUNDED:
2013
LEADERSHIP:
Founder and CEO: Akseli Hemminki
26 articles about TILT Biotherapeutics Ltd.
-
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
4/10/2024
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research Annual Meeting 2024.
-
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
2/14/2024
TILT Biotherapeutics announces it has been selected by the U.S. Department of Defense, America’s largest government agency, to receive a USD 2M grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset.
-
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023
12/8/2023
TILT Biotherapeutics presented safety and efficacy data from its international Phase I trial in patients with metastatic melanoma, in an oral presentation at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
-
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
11/6/2023
TILT Biotherapeutics presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy of Cancer 2023 conference.
-
TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor
5/15/2023
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient has been dosed in a Phase I trial of the company’s oncolytic adenovirus TILT-123.
-
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
2/7/2023
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million round.
-
TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US
11/9/2022
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities.
-
TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
10/11/2022
TILT Biotherapeutics announces that the first US patient has been dosed in its ovarian cancer trial, using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication.
-
Equillium, 9 Meters Biopharma and ABVC Biopharma have something to say about lupus, short bowel syndrome and ADHD.
-
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer
9/26/2022
TILT Biotherapeutics announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy.
-
TILT Biotherapeutics Announces over $10 Million Financing to Advance Oncology Immunotherapy Assets
6/14/2022
TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has completed the first close of its financing round raising $10.7 million (€10 million).
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
3/31/2022
TILT Biotherapeutics, a clinical-stage biotechnology company developing oncolytic immunotherapy for enabling therapies based on T cells, such as immune checkpoint inhibitors and adoptive cell therapies, announces positive interim progress and safety data from its phase 1 clinical trials in metastatic melanoma and solid tumors.
-
TILT Biotherapeutics Announces Data at ESMO on Its Oncolytic Immunotherapy Platform
9/17/2021
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that the company presented yesterday clinical study results at the annual congress of the European Society of Molecular Oncology.
-
TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
8/27/2021
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that new preclinical data relating to the use of its oncolytic immunotherapy platform for expressing a human IL-2 variant protein has been published in Frontiers in Immunology.
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
6/14/2021
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.
-
TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial
5/5/2021
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus.
-
TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer
4/14/2021
TILT Biotherapeutics announced a clinical trial collaboration agreement with MSD, a premier research-intensive biopharmaceutical company, to evaluate TILT’s adenoviral cancer immunotherapy TILT-123, a dual cytokine armed oncolytic adenovirus, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy, in a Phase I dose escalation trial in platinum resistant or refractory ovarian cancer.
-
TILT Biotherapeutics Announces Two Patients Pass Primary Safety Endpoint in European Cancer Immunotherapy Trial
9/28/2020
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmark’s Herlev hospital in Copenhagen.